CALT实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 May 2024 @ 04:00):

Stats
今日成交量	4 760.00
平均成交量	6 716.00
市值	535.11M
EPS	$0 ( 2024-02-21 )
下一个收益日期	( $-0.140 ) 2024-05-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-12.54
ATR14	$0 (0.00%)

Calliditas Therapeutics 相关性

10 最正相关
BLPH	0.931
ASLN	0.922
ORTX	0.916
KBAL	0.908
UNCY	0.902
ADMS	0.888
ALBO	0.887
PLPC	0.884
CMPI	0.879
CPTA	0.877

10 最负相关
CARA	-0.92
STIM	-0.908
ACNB	-0.906
VEON	-0.902
TVACW	-0.899
CPTN	-0.899
ALEC	-0.898
PCB	-0.896
CBAN	-0.895
BRKL	-0.893

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Calliditas Therapeutics 财务报表

Annual	2023
营收:	$1.21B
毛利润:	$1.13B (93.62 %)
EPS:	$-8.69

FY	2023
营收:	$1.21B
毛利润:	$1.13B (93.62 %)
EPS:	$-8.69

FY	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$0

FY	2022
营收:	$802.88M
毛利润:	$787.68M (98.11 %)
EPS:	$-7.78

Financial Reports:

No articles found.

Calliditas Therapeutics

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.